TRT + GLP-1 Stacking: The Evidence for Combining Testosterone and Semaglutide/Tirzepatide

Roughly a third of men with obesity meet biochemical criteria for hypogonadism, and that prevalence climbs with waist circumference and BMI. When a hypogonadal man starts a GLP-1 for weight loss, two clinical questions arrive on the same day: do the drugs interact, and does adding testosterone replacement therapy to semaglutide or tirzepatide do anything beyond what either does alone? The published evidence is narrower than the marketing on TRT-clinic websites would suggest — but it is not empty. TRAVERSE (Lincoff 2023 NEJM^[1]) cleared the cardiovascular safety question in hypogonadal men with elevated CV risk. T4DM (Wittert 2021 Lancet Diabetes Endocrinol^[5]) established that adding testosterone to a lifestyle programme reduces fat mass and prevents progression to type 2 diabetes in middle-aged men with low T. Seminara 2026 (Minerva Endocrinol^[12]) is the first pilot study of testosterone undecanoate specifically added to tirzepatide in obese hypogonadal late responders. Below: what we know, what we do not, the interaction risk with oral testosterone formulations, and the monitoring protocol.

The honest summary

• TRT is for hypogonadism, not for weight loss alone. Endocrine Society guidance (Bhasin 2018^[2]) requires total testosterone below 300 ng/dL on two separate morning draws plus symptoms. Prescribing testosterone for a eugonadal man purely to amplify GLP-1 fat loss is off-label, against guideline, and exposes the patient to erythrocytosis, PSA flux, and HPG-axis suppression with no documented benefit.
• Cardiovascular safety is now adequate. TRAVERSE^[1] randomized 5,246 men aged 45–80 with hypogonadism and either established CVD or high CV risk to transdermal testosterone or placebo. Mean follow-up ~22 months. Primary MACE outcome was non-inferior. That settles a decade of regulatory uncertainty for the population that overlaps most with GLP-1 candidacy.
• Weight effect of TRT alone is modest. The Saad 2016 long-term registry^[3] (411 hypogonadal men, mean follow-up ~5 years on testosterone undecanoate) reported sustained weight reductions and waist circumference improvements — but this is an observational registry, not an RCT, and lifestyle confounding is not controlled. Randomized data from T4DM and Ng Tang Fui demonstrate fat-mass reductions of ~3–5 kg on top of a caloric deficit, considerably less than GLP-1 monotherapy delivers.
• Direct stacking data is one pilot study. Seminara 2026^[12] — the only published study of TRT added to a GLP-1 specifically — tested testosterone undecanoate in obese hypogonadal men who had plateaued on tirzepatide. The combination produced further fat-mass loss with apparent preservation of lean mass versus tirzepatide continuation alone. It is a small pilot. Treat the magnitude as preliminary.
• The interaction risk is real but narrow. GLP-1 receptor agonists slow gastric emptying. The Calvarysky 2024 systematic review^[11] identified clinically relevant absorption effects for oral medications with narrow therapeutic windows or pH-dependent dissolution. Oral testosterone undecanoate (Jatenzo, Kyzatrex, Tlando) requires a fat-containing meal for lymphatic absorption — the appetite suppression and gastroparesis-like effects of high-dose tirzepatide can interfere. Injectable testosterone cypionate and enanthate are not affected.

Why obese men are often hypogonadal

The European Male Ageing Study (Camacho 2013^[4]) documented the bidirectional relationship in 3,369 men aged 40–79 followed longitudinally. Weight gain lowered total and free testosterone; weight loss raised both. The dominant mechanisms are well-characterized: aromatization of androgens to estradiol in adipose tissue suppresses hypothalamic GnRH; chronic low-grade inflammation in visceral fat reduces Leydig-cell steroidogenesis; sleep apnea (highly comorbid with obesity) blunts the nocturnal LH pulse that drives the morning testosterone peak. The relevant clinical implication: in a man with BMI ≥ 32 and total T in the low-200s, weight loss alone may restore the axis. The Camacho cohort showed that men who lost ≥ 15% body weight had statistically significant rises in total and free T at 4-year follow-up.

Practical sequencing: the Bhasin guideline predates the weight-loss GLP-1 indication, but the underlying principle (treat hypogonadism only when it is biochemically and symptomatically present and unlikely to resolve with reversal of the underlying cause) argues for re-checking total and free T at week 12 of GLP-1 therapy before committing to TRT in men with borderline hypogonadism.

TRAVERSE: the cardiovascular question is answered

TRAVERSE (Lincoff 2023 NEJM^[1]) was the FDA post-marketing requirement after the 2014 boxed-warning controversy. Design: randomized, double-blind, placebo-controlled, n=5,246, men 45–80 with total T below 300 ng/dL on two morning draws plus hypogonadal symptoms and either established cardiovascular disease or high CV risk. Intervention: 1.62% transdermal testosterone gel titrated to a target total T of 350–750 ng/dL. Primary outcome: MACE composite of death from cardiovascular causes, non-fatal MI, or non-fatal stroke. Mean follow-up 21.7 months.

Result: testosterone met the non-inferiority margin (hazard ratio 0.96, 95% CI 0.78–1.17). Secondary signals worth noting: a small but statistically significant increase in atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm. The PE signal is a known TRT class effect (erythrocytosis-mediated). The clinical implication for GLP-1 co-therapy is that the cardiovascular safety net for TRT is now built, but the VTE/hematocrit monitoring requirement is not relaxed.

T4DM: TRT plus lifestyle in middle-aged men with low T

T4DM (Wittert 2021^[5]) is the cleanest randomized evidence for testosterone added to a structured weight-loss programme. Design: 1,007 men aged 50–74 with waist ≥ 95 cm, impaired glucose tolerance or newly-diagnosed T2D, and serum testosterone ≤ 14.0 nmol/L (~403 ng/dL). All participants entered a 6-week lifestyle programme (Weight Watchers-based) and were then randomized to testosterone undecanoate 1,000 mg IM every 3 months plus lifestyle vs placebo plus lifestyle for 2 years.

At 2 years, the testosterone arm had a lower 2-hour oral glucose tolerance test glucose, a 41% relative reduction in the proportion meeting T2D criteria, and a mean additional fat mass loss of approximately 2–3 kg vs lifestyle alone. Lean mass was preserved. The secondary QoL/psychosocial analysis (Grossmann 2024^[6]) found improvements in sexual desire and energy/vitality. T4DM established the principle that, in symptomatic hypogonadal men, adding testosterone to caloric restriction improves both body composition and metabolic outcomes beyond the lifestyle effect.

Caveat: T4DM's comparator was lifestyle alone, not GLP-1. The incremental benefit of TRT layered on top of semaglutide 2.4 mg or tirzepatide 15 mg is the question Seminara 2026 attempts to address with a pilot dataset.

Ng Tang Fui 2017: lean-mass preservation evidence

The Ng Tang Fui Clin Endocrinol 2017 trial^[7] randomized 100 men aged 18–75 with BMI ≥ 30 and total T < 12 nmol/L to testosterone undecanoate 1,000 mg IM at baseline, weeks 6, 18, 30, 42, and 54 vs placebo, all on a very-low-calorie diet for 10 weeks followed by 46 weeks of weight maintenance. The testosterone arm lost more total body fat and preserved more lean mass during the VLCD and maintenance phases. The important nuance: the body composition benefit was not sustained 18 months after cessation of testosterone — underscoring that TRT is a chronic therapy for chronic hypogonadism, not a body recomposition cycle.

Seminara 2026: the direct TRT + tirzepatide pilot

Seminara and colleagues^[12] (Minerva Endocrinol, published in 2026) ran the only published pilot specifically testing TRT add-on to a GLP-1 in the late-responder population. Obese hypogonadal men who had plateaued on tirzepatide were given testosterone undecanoate as add-on therapy. Outcome: additional fat-mass reduction and preserved lean mass versus tirzepatide continuation alone. As a single-site pilot study, the result is hypothesis-generating, not practice-defining — but it is the most direct TRT + GLP-1 dataset published as of mid-2026. A larger randomized trial would settle the magnitude.

Mechanistic rationale for the stack

GLP-1 trials in non-hypogonadal populations indicate that approximately 25–30% of the total weight lost is lean mass — STEP-1^[8] (semaglutide 2.4 mg −14.9% body weight) and SURMOUNT-1^[9] (tirzepatide −20.9%) generated the body-composition substudy data that informs this estimate. The clinical worry in obese hypogonadal men is that low baseline anabolic drive compounds the lean-mass loss from caloric deficit. Testosterone's mechanism is opposite and additive: it upregulates muscle protein synthesis, increases satellite cell activation, and supports skeletal muscle integrity during energy restriction. T4DM and Ng Tang Fui both demonstrated lean-mass preservation on top of weight-loss intervention. The rational stack is therefore fat loss from GLP-1, lean-mass preservation from TRT — in patients who already meet hypogonadism criteria, not as cosmetic body recomposition for eugonadal men.

Magnitude context

Oral testosterone + GLP-1: the real interaction risk

Oral testosterone undecanoate formulations (Jatenzo, Kyzatrex, Tlando) bypass first-pass hepatic metabolism via intestinal lymphatic absorption, which requires the drug to be taken with a fat-containing meal. Two GLP-1 effects directly threaten this pharmacokinetic pathway. First, slowed gastric emptying delays the chyme that carries the drug to the proximal small bowel. Second, appetite suppression at higher GLP-1 doses can reduce dietary fat intake to the point where the lymphatic absorption pathway no longer engages. The Calvarysky 2024 systematic review^[11] documented clinically relevant absorption effects for several oral drug classes co-administered with GLP-1 RAs; oral testosterone formulations should be considered at risk.

Practical guidance: injectable testosterone cypionate or enanthate (IM or subcutaneous, typically 100–200 mg weekly), long-acting testosterone undecanoate injectable (Aveed), and transdermal gels bypass the absorption issue entirely. Oral formulations are not contraindicated but require monitored re-titration with confirmed adequate trough total T levels.

Monitoring protocol for the stack

Standard TRT monitoring (Bhasin 2018^[2]) is retained without modification when layered onto a GLP-1. The minimum dataset:

• Baseline: total testosterone (two AM draws), free testosterone, SHBG, estradiol, hematocrit, PSA (men ≥ 40), lipid panel, A1c, comprehensive metabolic panel.
• Week 12: total T (trough, 24 h before next IM dose), hematocrit, estradiol. Confirm therapeutic range (typically 400–700 ng/dL trough). If hematocrit > 54%, reduce dose or extend dosing interval; phlebotomy if clinically indicated.
• Week 24: total T, hematocrit, PSA, lipid panel. Continue dose if controlled; document weight trajectory on the GLP-1.
• Week 52: full repeat baseline panel. Re-evaluate continued TRT indication: persistent hypogonadism vs reversal with weight loss.
• Year 2+: every 6–12 months ongoing.

Provider routes

The major telehealth TRT clinics that prescribe injectable or transdermal testosterone with appropriate hypogonadism documentation are reviewed in our guide to the best TRT clinics, which covers their monitoring cadence and willingness to co-manage with GLP-1 prescribers.

What this article does not claim

• TRT is not a fat-burner for eugonadal men. Without biochemical hypogonadism and symptoms, the guideline does not support prescription and the evidence does not support a weight-loss-only indication.
• The direct stacking dataset is one pilot. Until a larger randomized trial of TRT + tirzepatide vs tirzepatide alone is published, stacking remains a reasonable clinical inference rather than a guideline-grade recommendation. The combined CV-safety inference rests on TRAVERSE and SELECT^[10] separately, not on a combined trial.

Related research

• TRT for weight loss: the full evidence review — TRAVERSE, T4DM, Ng Tang Fui, Saad registry, and the eligibility criteria
• Exercise pairing on a GLP-1 — the resistance-training half of lean-mass preservation
• Ozempic muscle loss: lean-mass protection evidence — SURMOUNT-1 body comp substudy and the 25% lean-mass-of-total-loss number
• Tirzepatide and muscle loss — SURMOUNT body composition data and the preservation playbook
• Creatine for lean-mass preservation on a GLP-1 — non-hormonal anabolic adjunct evidence
• Best TRT telehealth clinics — provider review including monitoring cadence

Important disclaimer. This article is educational and does not constitute medical advice. Testosterone replacement therapy in the United States is indicated only for men with biochemically confirmed hypogonadism (total testosterone below 300 ng/dL on two separate morning draws plus consistent symptoms, per the 2018 Endocrine Society Clinical Practice Guideline). TRT for weight loss in eugonadal men is off-label and not supported by the evidence reviewed here. Decisions about combining TRT with a GLP-1 should be made with an endocrinologist or obesity-medicine clinician, with current baseline labs in hand. PMIDs were verified live against the PubMed E-utilities API on 2026-05-28.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if a larger randomized trial of TRT + GLP-1 stacking is published.